Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.

European journal of clinical pharmacology - 1 Nov 2004

Miura M, Tada H, Yasui-Furukori N, Uno T, Sugawara K, Tateishi T, Suzuki T

Abstract excerpt

OBJECTIVE: The purpose of this study was to elucidate the pharmacokinetics of each enantiomer of lansoprazole and 5-hydroxylansoprazole in three different CYP2C19 genotype groups of Japanese subjects. METHODS: Healthy subjects ( n=18), of whom 6 were homozygous extensive metabolizers (homEMs), 6 were heterozygous extensive metabolizers (hetEMs) and 6 were poor metabolizers (PMs), participated in the study. After...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to 2-Pyridinylmethylsulfinylbenzimidazoles
Share to Administration, Oral

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Anti-Ulcer Agents

Share to Half-Life

Share to Lansoprazole

Share to Omeprazole

Share to Proton Pump Inhibitors

Share to Stereoisomerism

Source

Identifiers

PMID: 15448955
DOI: 10.1007/s00228-004-0809-1

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacokinetic differences between the enantiomers of lansoprazole and its metabolite, 5-hydroxylansoprazole, in relation to CYP2C19 genotypes.PMID 15448955Read ↗

Effect of clarithromycin on the enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Enantioselective disposition of lansoprazole and rabeprazole in human plasma.Semantic proximity Read ↗

Effects of CYP2C19 polymorphism on the pharmacokinetics of lansoprazole and its main metabolites in healthy Chinese subjects.Semantic proximity Read ↗

Metabolic disposition of lansoprazole in relation to the S-mephenytoin 4'-hydroxylation phenotype status.Semantic proximity Read ↗

Pharmacokinetics of lansoprazole in Chinese healthy subjects in relation to CYP2C19 genotypes.Semantic proximity Read ↗

Enantioselective disposition of lansoprazole in relation to CYP2C19 genotypes in the presence of fluvoxamine.Semantic proximity Read ↗

The (R)-omeprazole hydroxylation index reflects CYP2C19 activity in healthy Japanese volunteers.Semantic proximity Read ↗

Hydroxylation of R(+)- and S(-)-omeprazole after racemic dosing are different among the CYP2C19 genotypes.Semantic proximity Read ↗

Genetic polymorphism of CYP2C19 and lansoprazole pharmacokinetics in Japanese subjects.Semantic proximity Read ↗

Pharmacokinetics of three proton pump inhibitors in Chinese subjects in relation to the CYP2C19 genotype.Semantic proximity Read ↗

Correlation between R/S enantiomer ratio of lansoprazole and CYP2C19 activity after single oral and enteral administration.Semantic proximity Read ↗

Effects of genetic polymorphisms of CYP2C19*2/*3 and MDR1 C3435T on the pharmacokinetics of lansoprazole in healthy Chinese subjects.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.